Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





WHO Changes SARS-CoV-2 Virus Test Criteria to Reduce False Positives

By LabMedica International staff writers
Posted on 25 Jan 2021
In its updated guidance, the World Health Organization (WHO; Geneva, Switzerland) has cautioned experts not to rely solely on the results of a PCR test to detect the SARS-CoV-2 virus and consider the results in combination with other factors such as timing of sampling, specimen type, and assay specifics, among others.

The WHO has updated its guidance on nucleic acid testing (NAT) technologies that use polymerase chain reaction (PCR) for the detection of SARS-CoV-2. More...
It has requested users to follow the instructions for use (IFU) when interpreting results for specimens tested using PCR methodology. The WHO has advised users of IVDs to read and follow the IFU carefully to determine if manual adjustment of the PCR positivity threshold is recommended by the manufacturer.

According to the WHO’s guidance on diagnostic testing for SARS-CoV-2, careful interpretation of weak positive results is needed as the cycle threshold (Ct) needed to detect the virus is inversely proportional to the patient’s viral load. Where test results do not correspond with the clinical presentation, it recommends that a new specimen should be taken and retested using the same or different NAT technology.

The WHO has reminded IVD users that disease prevalence alters the predictive value of test results; as disease prevalence decreases, the risk of false positive increases. This means that the probability that a person who has a positive result (SARS-CoV-2 detected) is truly infected with SARS-CoV-2 decreases as prevalence decreases, irrespective of the claimed specificity. Since most PCR assays are indicated as an aid for diagnosis, the WHO has advised health care providers to consider any results in combination with the timing of sampling, specimen type, assay specifics, clinical observations, patient history, confirmed status of any contacts, and epidemiological information.

Related Links:
World Health Organization (WHO)


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
New
Hematology Consumables
Bioblood Devices
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.